Why the study?
Does inhaled iloprost improve pulmonary hemodynamics and facilitate weaning from cardiopulmonary bypass in patients with chronic pulmonary hypertension undergoing mitral valve surgery?
Does inhaled iloprost improve pulmonary hemodynamics and facilitate weaning from cardiopulmonary bypass in patients with chronic pulmonary hypertension undergoing mitral valve surgery?
Inhaled iloprost acts as a selective pulmonary vasodilator, improving right ventricular performance and facilitating weaning from cardiopulmonary bypass in patients with pulmonary hypertension undergoing mitral valve surgery.
Answers are grounded in this paper and cite their sources.
Supports inhaled iloprost for right ventricular support during mitral valve surgery; extends RCT evidence for selective pulmonary vasodilation in chronic pulmonary hypertension.
BACKGROUND: Pulmonary hypertension (PHT) is common in patients undergoing mitral valve surgery and is an independent risk factor for the development of acute right ventricular (RV) failure. Inhaled iloprost was shown to improve RV function and decrease RV afterload in patients with primary PHT. However, no randomized-controlled trials on the intraoperative use of iloprost in cardiac surgical patients are available. We therefore compared the effects of inhaled iloprost vs. intravenous standard therapy in cardiac surgical patients with chronic PHT. METHODS: Twenty patients with chronic PHT undergoing mitral valve repair were randomized to receive inhaled iloprost (25 microg) or intravenous nitroglycerine. Iloprost was administered during weaning from cardiopulmonary bypass (CPB). Systemic and pulmonary haemodynamics were assessed with pulmonary artery catheterization and transoesophageal echocardiography. Milrinone and/or inhaled nitric oxide were available as rescue medication in case of failure to wean from CPB. RESULTS: Inhaled iloprost selectively decreased the pulmonary vascular resistance index after weaning from CPB (208 +/- 108 vs. 422 +/- 62 dyn.s/cm(5)/m(2), P<0.05), increased the RV-ejection fraction (29 +/- 3% vs. 22 +/- 5%, P<0.05), improved the stroke volume index (27 +/- 7 vs. 18 +/- 6 ml/m(2), P<0.05) and reduced the transpulmonary gradient (10 +/- 4 vs. 16 +/- 3 mmHg, P<0.05). In all patients receiving inhaled iloprost, weaning from CPB was successful during the first attempt. In contrast, three patients in the control group required re-institution of CPB and had to be weaned from CPB using rescue medication. CONCLUSIONS: In patients with pre-existing PHT undergoing mitral valve surgery, inhaled iloprost is superior to intravenous nitrogylycerine by acting as a selective pulmonary vasodilator, reducing RV afterload and moderately improving RV-pump performance.
No takes yet. Share an insight, caveat, or question.
Rex et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: